These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1659054)

  • 1. Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus.
    Hall SL; Murphy BR; van Wyke Coelingh KL
    Vaccine; 1991 Sep; 9(9):659-67. PubMed ID: 1659054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2017 Dec; 35(51):7139-7146. PubMed ID: 29153777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats.
    Ambrose MW; Wyde PR; Ewasyshyn M; Bonneau AM; Caplan B; Meyer HL; Klein M
    Vaccine; 1991 Jul; 9(7):505-11. PubMed ID: 1654680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys.
    Tang RS; Mahmood K; Macphail M; Guzzetta JM; Haller AA; Liu H; Kaur J; Lawlor HA; Stillman EA; Schickli JH; Fouchier RA; Osterhaus AD; Spaete RR
    Vaccine; 2005 Feb; 23(14):1657-67. PubMed ID: 15705469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.
    van Wyke Coelingh KL; Winter CC; Tierney EL; Hall SL; London WT; Kim HW; Chanock RM; Murphy BR
    J Virol; 1990 Aug; 64(8):3833-43. PubMed ID: 1695256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines.
    Lehman DJ; Roof LL; Brideau RJ; Aeed PA; Thomsen DR; Elhammer AP; Wathen MW; Homa FL
    J Gen Virol; 1993 Mar; 74 ( Pt 3)():459-69. PubMed ID: 8383178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prototype recombinant vaccine against respiratory syncytial virus and parainfluenza virus type 3.
    Du RP; Jackson GE; Wyde PR; Yan WY; Wang Q; Gisonni L; Sanhueza SE; Klein MH; Ewasyshyn ME
    Biotechnology (N Y); 1994 Aug; 12(8):813-8. PubMed ID: 7765021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effects of monoclonal antibodies against parainfluenza virus type 3-induced brain infection in hamsters.
    Rydbeck R; Löve A; Norrby E
    J Gen Virol; 1988 May; 69 ( Pt 5)():1019-24. PubMed ID: 2836547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
    Tao T; Skiadopoulos MH; Durbin AP; Davoodi F; Collins PL; Murphy BR
    Vaccine; 1999 Mar; 17(9-10):1100-8. PubMed ID: 10195620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
    Spriggs MK; Murphy BR; Prince GA; Olmsted RA; Collins PL
    J Virol; 1987 Nov; 61(11):3416-23. PubMed ID: 2822951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
    Spriggs MK; Collins PL; Tierney E; London WT; Murphy BR
    J Virol; 1988 Apr; 62(4):1293-6. PubMed ID: 2831389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property.
    Ray R; Galinski MS; Compans RW
    Virus Res; 1989 Feb; 12(2):169-80. PubMed ID: 2539707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4.
    Stewart-Jones GBE; Chuang GY; Xu K; Zhou T; Acharya P; Tsybovsky Y; Ou L; Zhang B; Fernandez-Rodriguez B; Gilardi V; Silacci-Fregni C; Beltramello M; Baxa U; Druz A; Kong WP; Thomas PV; Yang Y; Foulds KE; Todd JP; Wei H; Salazar AM; Scorpio DG; Carragher B; Potter CS; Corti D; Mascola JR; Lanzavecchia A; Kwong PD
    Proc Natl Acad Sci U S A; 2018 Nov; 115(48):12265-12270. PubMed ID: 30420505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.
    Wyatt LS; Shors ST; Murphy BR; Moss B
    Vaccine; 1996 Oct; 14(15):1451-8. PubMed ID: 8994321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.